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Abstract
Children and young adults of reproductive age have emerged as groups that are highly vulnerable to the current
2009 H1N1 pandemic. The sex of an individual is a fundamental factor that can influence exposure, susceptibility
and immune responses to influenza. Worldwide, the incidence, disease burden, morbidity and mortality rates fol-
lowing exposure to the 2009 H1N1 influenza virus differ between males and females and are often age-dependent.
Pregnancy and differences in the presentation of various risk factors contribute to the worse outcome of infection
in women. Vaccination and antiviral treatment efficacy also vary in a sex-dependent manner. Finally, sex-specific
genetic and hormonal differences may contribute to the severity of influenza and the clearance of viral infection.
The contribution of sex and gender to influenza can only be determined by a greater consideration of these fac-
tors in clinical and epidemiological studies and increased research into the biological basis underlying these
differences.
Sex, gender and pregnancy in the 2009 H1N1
pandemic
Sex and gender differences can affect exposure to patho-
gens, vulnerability to infectious diseases, health seeking
behaviours and immune responses to pathogens, result-
ing in differences between males and females in the
incidence, duration, severity and case fatality rates fol-
lowing an infection [1,2]. Sex refers to the biological
and physiological characteristics that define males and
females, whereas gender refers to the roles, behaviours,
activities and attributes that individual societies consider
appropriate for men and women. The impact of sex and
gender on infection is tied to the age of the individual,
as both biological and cultural factors can change dra-
matically with age. Consideration of these factors can
result in a more effective public health response to
infectious diseases, including influenza, and yet they are
often inadequately addressed in clinical and basic
research studies. A systematic review of the literature
regarding sex, gender, pregnancy and the 2009 H1N1
pandemic indicates these are important factors which
alter the severity of the disease as well as the prevention
and treatment measures. A greater awareness of how
sex and gender impact upon the biology of 2009 H1N1
infection could provide important insights into the




An influenza pandemic was declared by the World
Health Organization (WHO) in June 2009 and the
virus, 2009 H1N1, became the primary influenza virus
strain isolated from humans by the end of the winter
influenza season in the southern hemisphere [3]. It was
the dominant influenza A virus strain circulating in the
northern hemisphere for the entire influenza season,
effectively outcompeting both seasonal influenza A virus
strains [3].
Biological factors associated with severe 2009 H1N1
infection
The pandemic has been termed mild due to the rela-
tively low mortality. Confirmed influenza virus infec-
tions, however, have increased substantially compared to
recent years and the US Center for Disease Control
(CDC) estimates of the number of people infected with
2009 H1N1 are greater than what would be expected in
a standard influenza season [3].
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Younger age
Most cases of severe disease and mortality after infec-
tion with seasonal influenza A virus occur in the ≥65
years population. In contrast, 2009 H1N1 has not been
associated with a large number of infections in this age
group but has the highest attack and hospitalization
rates in individuals between the ages of 0-40. The
reduced number of cases in those aged ≥65 stems in
part from the fact that antibodies generated to pre-
1950 H1N1 viruses cross react with 2009 H1N1,
resulting in limited protection from 2009 H1N1 infec-
tion [3].
Presence of co-morbidities or risk factors for severe disease
Several populations are at risk for severe disease from
seasonal as well as 2009 H1N1 infection [4], including
individuals who have pre-existing illnesses or medical
conditions, pregnant women, immunosuppressed indi-
viduals (either through treatment, HIV infection, or
as a result of a pre-existing immunosuppressive disor-
der) and children aged 0-4 years. Medical conditions
associated with an increased risk of severe disease
include chronic respiratory disorders (for example,
asthma, bronchitis, chronic obstructive pulmonary
disease [COPD] and cystic fibrosis), neuromuscular
disorders (for example, cerebral palsy, myasthenia
gravis and muscular dystrophy), metabolic diseases
(for example, diabetes) and chronic renal, heart or
liver disorders [3]. Factors such as obesity and hyper-
tension are not normally associated with severe dis-
ease from seasonal influenza but have been suggested
as risk factors for severe disease from 2009 H1N1 in
some studies [5-7].
Host immune responses
The protective immunity induced by influenza vaccina-
tions is mediated primarily by antibodies that recognize
the viral haemagglutinin protein and neutralize virus
infectivity. After virus infection, host innate immune
responses, including production of cytokines and che-
mokines, are activated which initiate a cascade of immu-
nological events that lead to the development of specific
immune responses to the virus. Controlling and clearing
influenza virus infection requires neutralizing antibodies
and cell-mediated immunity (for example, activation of
T cells) [3]. The influx of immune cells into an influ-
enza-infected lung can lead to the overproduction of
various cytokines and chemokines - often called a ‘cyto-
kine storm’ - which can enhance the virus-induced lung
damage resulting in severe illness. A limited number of
studies suggest that an altered cytokine and chemokine
response is contributing to severe 2009 H1N1 disease
[8,9]. Therefore, immunity to influenza viruses repre-
sents a balance between immune responses inducing
protection and clearance of virus versus causing
pathology.
Male-female differences in 2009 H1N1-related morbidity
and mortality
Utilizing published observational reports of patients with
confirmed 2009 H1N1 infection and those admitted into
intensive care units worldwide, the incidence, severity
and case fatality rates following infection appear to differ
between males and females, but often are age-dependent
and vary between countries. The outcome of infection
with 2009 H1N1 is generally worse for females, but the
magnitude of this difference varies across geographical
regions.
Incidence
Assessments of male-female differences in reported inci-
dences of infection is confounded by two factors: (1)
many countries do not disaggregate data by both sex
and age which may mask sex differences among the age
groups that are most likely to be exposed - children and
young adults; and (2) the profound differences in health
seeking behaviours between males and females [10].
Household transmission studies of children and adults
reveal that being female (female relative risk [RR]: 1.87,
95% confidence interval [CI]: 1.17-2.73) is a significant
factor associated with higher secondary attack rates of
influenza-like illness, with attack rates being higher
among children and young adults than older adults (>55
years of age) [11]. Reported male-female differences in
the incidence of infection vary with age in several coun-
tries, with a higher incidence of infection with 2009
H1N1 in young women than young men of comparable
age [12-15]. While pregnancy has been clearly linked
with increased disease severity, the vast majority of
infected females of reproductive ages are not pregnant,
suggesting that additional factors are contributing to the
increased incidence of infection. In contrast, in Asia, the
majority of reported H1N1 cases have been male
(57.1%) [16,17]. In China, males (male odds ratio [OR]:
1.94, 95% CI: 1.07-2.66) also shed the 2009 H1N1 virus
in pharyngeal and nasopharyngeal samples for a longer
duration than females [18] suggesting that the transmis-
sion potential may be higher in males. Other countries
reported no male-female differences in the number of
cases of 2009 H1N1, but did not analyse the data strati-
fied by both age and sex [19-25].
Morbidity
One trend that appears consistent across more than 60%
of the datasets evaluated is that more females are hospi-
talized with critical illness than males (Figure 1). The
first cases in the USA were in California (April-May
2009), where the a majority of hospitalized cases (21/26)
were women, five of whom were pregnant [26]. Initial
analyses of data from critically ill patients in the USA
during the first wave reported no male-female difference
[27], but subsequent state-specific reports from the first
and second waves illustrated differences between the
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sexes [28-30]. In Canada, a significant majority of criti-
cally ill patients have been young women (female RR:
1.3, 95% CI: 1.0-1.6) [5,31]. Other countries also report
that rates of hospitalization have been higher among
females than males, with a majority of the females being
of reproductive age (15-49 years of age) [14,32-36]. Ana-
lyses of cohorts of patients in Mexico and Australia/
New Zealand revealed a trend for more females than
males being hospitalized [6,37]. Evaluation of these dif-
ferences in some countries is confounded by age, as
many studies do not report male-female differences
according to age group [6,27,37].
An examination of sex differences disaggregated by
age is needed in larger, more complete datasets. The
reason for the greater proportion of hospitalized women
is not known, but many cases involve co-morbid condi-
tions, including chronic respiratory diseases (for exam-
ple. asthma and COPD), which are often more severe in
females [38-40].
Mortality
Mortality from 2009 H1N1 is not common but data
from South Africa, where the incidence of co-infection
with HIV and tuberculosis is high, reveal that 65% of
fatal cases were females of reproductive age, of whom
almost half were pregnant [41]. RR of death is higher
for young adult women (female RR: 1.5, 95% CI: 0.9-2.3)
than men in Canada [31]. In Australia, 58% of fatal
cases were male [35] and in Brazil and Peru case fatality
rates have been equal between males and females
[14,20]. No consistent pattern of male-female differences
in mortality from the 2009 H1N1 has emerged.
Effects of pregnancy on the severity of 2009 H1N1
disease
Increased morbidity and mortality in pregnant women
has been documented during influenza pandemics and
influenza seasons where virus infection rates are particu-
larly high [42].
Morbidity and mortality
Pregnant women represent a disproportionately higher
percentage of severe cases with the increased risk ran-
ging from four- to 10-fold greater compared with the
general population (Figure 2). Increased morbidity and
mortality in pregnant women has been reported in
many datasets [5,14,27,28,36,37,41,43-45]. The disease
course and clinical presentation [46-48] has been stu-
died and comparisons of disease in pregnant women to
age-matched non-pregnant women [37,49,50] or to the
general population [51] have been made. Disease sever-
ity is increased during the second and third trimester.
However, no clear clinical parameter has been asso-
ciated with pregnancy-associated increased morbidity
and mortality. There are no significant differences in the
general symptoms of disease, the progression to viral
pneumonia, acute respiratory distress syndrome (ARDS)
or secondary bacterial pneumonia in pregnant women
compared to the control populations. Severe disease was
also associated with a greater than sixfold increase in
adverse neonatal outcomes when compared with preg-
nant women suffering mild disease [49]. An increased
risk of severe disease may be present during the early
postpartum period but the reported number of cases is
limited and requires additional investigation [37,50].
Figure 1 Rates of hospitalization with severe 2009 H1N1 are higher among females than males in a majority of published datasets.
Female to male ratios of hospitalization with confirmed 2009 H1N1 were calculated using published datasets [5,6,14,16,27-30,32-37,43,134-136].
Pink bars = higher rates of hospitalization in females; blue bars = higher rates of hospitalization in males; grey bars = similar hospitalization rates
in males and females. Details about sample sizes, time of data collection, and criteria for hospitalization are contained within each individual
reference.
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Risk factors
Pregnancy itself is considered a risk factor for severe
disease [3] but the biological basis for this has not been
established. Pregnancy-associated changes in immune
function, hormone levels, cardiopulmonary stress and
difficulties in treatment for respiratory disease are often
cited as important factors [52]. The presence of other
risk factors may increase the risk of severe disease in a
pregnant woman (Figure 3). The presence of a known
co-morbidity in pregnant women with severe 2009
H1N1 disease can vary greatly and has been documen-
ted as 16% to 56% [37,46-50,53]. There is no one or
cluster of co-morbidities associated with increased dis-
ease severity in pregnant women. Data indicate that
when no additional co-morbidities were present, preg-
nant women still had a seven- to tenfold higher rate of
severe disease when compared to age-matched, non-
pregnant women [49,50].
Male-female differences in risk factors for severe 2009
H1N1 disease
Certain risk factors predispose patients to increased
morbidity and mortality following exposure to influenza
viruses [54] and the severity and prevalence of these
underlying conditions often differ between males and
females (Figure 4). The 2009 H1N1 virus causes
disproportionate disease among young adults, a popula-
tion that has a distinct repertoire of risk factors asso-
ciated with exposure and worse outcome following
infection compared with very young or old.
Occupational risk
Healthcare workers, as well as those in frequent contact
with young children, are at a higher risk of exposure to
influenza viruses than the general public [55]. Women
represent over 50% of the healthcare workforce in many
countries and nurses, teachers of young children and
day-care workers are predominantly female [10] which
potentially leads to a gender-specific occupational risk
for influenza acquisition.
Personal hygiene
Hand hygiene compliance, one of the most effective
ways to prevent transmission of influenza, is significantly
better among female than male (male OR: 0.6, 95% CI:
0.4-0.98) healthcare workers [56]. Among healthcare
workers in the USA, self-reported rates of use and
knowledge about appropriate personal protective equip-
ment in response to influenza are similar between the
sexes [57].
Health seeking behaviour
Differences in health seeking behaviour or healthcare
access may impact both the acquisition and manifesta-
tion of influenza. A WHO survey in 59 countries from
2002-2004 revealed that adult women are more likely to
seek healthcare in both higher and lower income coun-
tries [10]. The quality of care for women in some parts
of the developing world is not equal to that received by
men [58]. In some developing countries, knowledge of
the pandemic was higher among men than women,
which might reflect the fact that there are greater edu-
cational opportunities and greater chances of socializa-
tion for men [59].
Chronic diseases
Chronic medical conditions predispose patients to
increased influenza-related morbidity [54,60] and male-
female, as well as pregnancy-associated, differences in
disease prevalence have been reported.
(1) Respiratory disease Asthma has been a significant
underlying condition in children and adults hospitalized
with critical illness [27,61]. Data from the USA and
Canada illustrate that, prior to puberty, boys have more
asthma exacerbations than girls. However, this trend is
reversed in adulthood [39]. Rates of asthma attacks,
numbers of asthma-related emergency room visits, num-
bers of asthma-related hospitalizations and duration of
hospitalization are higher in women than men in the
USA [39,62]. Rates of asthma, as well as incidence of
asthma attacks, appear to be the same in pregnant and
age-matched non-pregnant women [63].
Cystic fibrosis and COPD have been identified as risk
factors for severe illness with 2009 H1N1 [3] and the
Figure 2 Rates of severe influenza disease among pregnant
women and the general population. Estimated morbidity rates
from April to December, 2009 for the 2009 H1N1 pandemic in
select countries or geographic regions. Morbidity estimates are
calculated based on datasets for the USA [27], Chicago, IL, USA [28],
California, USA [43], New York, USA [49], Australia and New Zealand
[37], Canada [5] and Brazil [14]. Estimates of the general population
and pregnant woman are based on data from the US Census
Bureau or the World Health Organization.
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progression of cystic fibrosis and long-term survival is
significantly worse for females than males, especially
among individuals diagnosed in childhood [64]. Females
with COPD report worse symptoms, lower exercise
capacity, more airway hyper-responsiveness and worse
health-related quality of life than males [65,66].
Although morbidity from these conditions may be
worse in females, mortality - both from all causes and
from respiratory-related disease alone - is still higher in
males with COPD [65], illustrating the complexities
involved in assessing the significance of sex and gender
for a particular co-morbidity.
(2) Hepatic disease Chronic hepatic disease is a risk
factor for severe 2009 H1N1 disease [3]. The develop-
ment of hepatocellular carcinoma occurs at a 2:1 to 4:1
ratio for males to females [67]. The prevalence of serum
hepatitis B virus (HBV) is consistently higher in men
than women [68]. Males are more than twice as likely to
die from liver cancer, which suggests that men may be
more sensitive to the effect of HBV infection on the
development of liver cancer [69]. Men also are twice as
likely to develop cirrhosis [70].
(3) Cardiovascular disease The rates and severity of
cardiovascular disease differ between the sexes and these
differences have been evaluated in the elderly [71]. As
they have not been identified as an at-risk population for
severe disease from 2009 H1N1 influenza, sex differences
in cardiovascular disease may not be a critical factor.
(4) Metabolic disorders Diabetes and morbid obesity
have emerged as novel risk factors for severe 2009
H1N1 disease [3]. The lifetime risk of diabetes is higher
in women than men, at least in the USA where approxi-
mately 55% of all diabetic-related deaths are women
which may be a reflection of the fact that women tend
to live longer than men [72]. In the USA, gestational
diabetes and rates of diabetes in obese adolescent girls
have been increasing [73,74]. Gestational diabetes occurs
in up to 14% of all pregnancies [75]. Women, particu-
larly those of lower socioeconomic status, also receive
less adequate diabetes care than men of the same socio-
economic status [76].
Females, particularly in developing countries, tend to
have higher rates of obesity [77]. According to the
WHO, in 138 of 195 countries, females are over 50%
Figure 3 Why are pregnant women at increased risk for severe 2009 H1N1 disease? While 2009 H1N1 infection results in increased
disease severity in pregnant women, the precise mechanisms responsible for this risk are not yet defined. The contribution of multiple biological
factors to disease severity needs to be more thoroughly investigated.
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more likely to be obese than males [78]. In some coun-
tries, the body mass index for women is 5-8 points
higher than for men [78]. The higher rates of obesity
and diabetes in females may be significant factors con-
tributing to higher 2009 H1N1-related morbidity in
women. It has not yet been determined whether pre-
pregnancy obesity or excess weight gain during preg-
nancy represent equivalent risks. Precise parameters for
documenting obesity in pregnant women have not been
established [79].
Immunocompromised individuals
Influenza in immunocompromised individuals is asso-
ciated with an increased severity of disease [54] and
HIV is recognized as a co-morbidity for 2009 H1N1
influenza [54,80]. The rate of HIV in females are
approaching that of males worldwide [81]. HIV RNA
levels are consistently lower in women than men [82].
However, women have a 1.6-fold higher risk of pro-
gression to AIDS than men with equal viral loads
[83,84]. There also are gender disparities in access to
care for women with HIV, with women traditionally
having greater difficulty accessing treatment [85,86].
Whether infection with HIV and progression to AIDS
differentially affects the outcome of influenza virus
infections in males and females has not been
evaluated.
Sex, gender and pregnancy effects on responses to
influenza vaccines and antiviral therapies
The precise impact of sex, gender and pregnancy on
responses to the 2009 H1N1 vaccines is not known
[87-90]. Data from clinical trials of seasonal influenza
vaccines reveal pronounced sex differences in the rates
of vaccination, antibody responses to the vaccines and
adverse reactions to the vaccines and illustrate that
these differences must be considered in response to the
2009 H1N1 vaccine. Seasonal influenza vaccination data
further reveal that pregnant and non-pregnant women
generate comparable immune responses and experience
similar adverse side effects [54].
Rates of vaccination
Available data on rates of 2009 H1N1 vaccination have
not been analysed by sex [91] but rates of seasonal influ-
enza vaccination vary significantly with respect to sex
and age [92-94]. Rates of vaccination among women are
lower than men in some European countries [92] and
may reflect greater negative beliefs about the risks asso-
ciated with vaccination [95], differences in physician
recommendations regarding vaccination or occupational
differences. Among healthcare workers in China, 73% of
women reported intentions to decline both the H5N1
and 2009 H1N1 vaccines compared to 64% of men [96].
In France, acceptance (either receipt or intention to
Figure 4 Sex and gender biases in risk factors and co-morbidities for severe 2009 H1N1 disease. Several risk factors predispose patients
to increased morbidity and mortality from 2009 H1N1. The likelihood of engaging in behaviors associated with increased exposure as well as
the severity and prevalence of co-morbidities associated with severe 2009 H1N1 disease differ between males and females.
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receive) of the 2009 H1N1 vaccine was higher among
men and was higher among pregnant women and other
groups with co-morbid conditions [97]. In the USA and
Canada, vaccination against seasonal and 2009 H1N1
influenza during pregnancy is recommended irrespective
of trimester [54,98,99]. The vaccination rate of pregnant
women against 2009 H1N1 virus has been estimated to
be only 38%, which is still higher than that normally
seen with seasonal influenza vaccine [91].
Antibody responses to vaccines
Numerous studies reveal that haemagglutination inhibi-
tion (HAI) titres following seasonal influenza vaccina-
tion are consistently higher in women than men of
comparable ages [100-104], which suggests that women
may be better protected against influenza disease follow-
ing vaccination than are men. Women aged 18-64 years
generate a more robust neutralizing antibody response
following vaccination than men [102]. Pregnant women
appear to have similar responses to seasonal influenza
vaccines compared to non-pregnant women. The
National Institutes of Health reports that 47 out of 50
(94%) pregnant women immunized with 2009 H1N1
vaccine achieved antibodies levels considered to be pro-
tective within 21 days of inoculation [105].
Adverse reactions to vaccines
Women report more severe local and systemic reactions
to influenza virus vaccines [100,102,104,106-108].
Women also experience worse reactions to vaccine adju-
vants [109], which should be considered for 2009 H1N1
vaccines that are administered with adjuvant [88,89].
The extent to which adverse reactions to the 2009
H1N1 vaccine differ in either frequency or severity
between males and females has not been reported [60].
Seasonal, H5N1 and MF-59-adjuvanted influenza vac-
cines are reported to be safe for pregnant women
[110-112]. A study of 50 pregnant women who received
the 2009 H1N1 vaccine reported it was well-tolerated
with no significant adverse side effects documented
[105].
Antiviral therapy
Antivirals are an effective treatment following infection
with influenza viruses when administered early during
the course of disease. The 2009 H1N1 viruses analysed,
to date, are all resistant to the adamantadine class of
antivirals but remain sensitive to neuraminidase inhibi-
tors [3]. Available data indicate that the rate of prescrib-
ing antivirals to seasonal influenza virus-infected
individuals, ranging in age from infants to adults, is
similar between males and females in the USA
[113-115]. In contrast, inappropriate prescription of
antibiotics for seasonal influenza is greater for women
[114]. A meta-analysis of data from randomized, double-
blind clinical trials illustrates that, following treatment
with oseltamivir, men return to their baseline wellness
faster than women, suggesting that antiviral treatment
for seasonal influenza may be more effective in men
[116]. Whether this observation reflects patient report-
ing biases, need for differential drug doses or other con-
founding factors is not clear. These data do, however,
indicate that sex and gender should be considered when
evaluating the efficacy of antiviral treatment for 2009
H1N1.
Prompt administration of neuraminidase inhibitors is
recommended for any pregnant woman with influenza-
like symptoms [3]. Administration of antivirals within
48 h of symptom onset correlates with a mild or
uneventful disease course in pregnant women [47,48,51].
Pregnant women who do not take antivirals, or begin
treatment >72 h after symptom onset, have significantly
higher morbidity and mortality rates compared to those
who have early antiviral treatment [48,49].
Sex differences in immune responses to viruses
Sex differences in the immune responses to influenza
viruses have not been systematically examined [117].
Using data from other virus-host systems, several immu-
nological, hormonal and genetic mechanisms have been
identified as being differentially expressed between the
sexes and altered during the course of pregnancy, which
may account for male-female differences and pregnancy-
associated increases in the severity of 2009 H1N1. Gen-
erally, women mount higher immune responses to viral
infections [118]. Heightened antiviral immunity in
women is beneficial for virus clearance, but may be det-
rimental if it becomes excessively high or prolonged,
leading to pathology and even death. Over the course of
pregnancy, inflammatory and antiviral immune
responses are suppressed which can alter responses to
viruses, such as influenza.
HIV
Women are at a greater risk of progressing to AIDS
than men, despite having significantly less HIV RNA in
circulation and host-mediated pathology is hypothesized
to contribute to this sex bias [82]. Plasmacytoid dentritic
cells (pDCs) are significant producers of type I interfer-
ons (IFN-a), which signal the activation of cytotoxic T
cells for the elimination of virally infected cells. pDCs
from women react more strongly to HIV-1 encoded
toll-like receptor 7 (TLR7) ligands than pDCs derived
from men, resulting in higher levels of immune cell acti-
vation [83]. Women with higher progesterone (P4) con-
centrations have greater numbers of activated pDCs in
response to the HIV TLR7 ligand than women with
lower P4 concentrations [83]. Several genes (for exam-
ple, the Tlr7 gene that encodes a receptor that recog-
nizes RNA viruses, including influenza viruses) that
encode for immunological proteins are on the X chro-
mosome and may escape X inactivation, resulting in
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higher amounts of expression in women [117]. X chro-
mosomal variation also alters the course of progression
of AIDS differently in women than men [84]. Whether
female-biased immunopathology contributes to the
severity of 2009 H1N1 disease in women requires
consideration.
Hepatitis B virus
The prevalence of HBV, titres of HBV DNA and devel-
opment of hepatocellular carcinoma are higher in males
than females and involve the effects of hormones on
viral and host gene expression [67,68,119]. Among HBV
positive males, elevated concentrations of testosterone
and expression of certain androgen receptor gene alleles
correlate with an increased risk of hepatocellular carci-
noma [120,121]. In HBV transgenic mice, castration of
males reduces, whereas replacement of testosterone in
castrated males increases, serum HBsAg concentrations
[122]. Chemically-induced hepatocellular carcinoma is
more severe in male than female mice, which is
mediated by increased inflammatory cytokine produc-
tion by liver cells in males and can be reversed with oes-
tradiol (E2) treatment [123]. Sex steroids modulate sex
differences in the prevalence of HBV and development
of liver cancer through effects on immune responses to
HBV. Whether sex steroids affect the pathogenesis of
influenza virus infection should be examined.
Sex steroids and immunity
The impact of sex steroids, including androgens, oes-
trogens and progesterone (P4), on the activity of
immune cells may contribute to sex differences and
the effects of pregnancy on responses to 2009 H1N1.
Generally, androgens, including dihydrotestoesterone
and testosterone, suppress the activity of immune cells
[124]. The immunosuppressive effects of androgens
may reflect the inhibitory effects of androgen receptor
signalling mechanisms on transcriptional factors that
mediate the production of pro-inflammatory and anti-
viral cytokines [125].
Oestrogens affect both innate and adaptive immune
function. Oestradiol can have bipotential effects with
low doses enhancing and high doses reducing proin-
flammatory cytokine production [126]. Low E2 concen-
trations promote helper T cell type 1 (Th1) responses
and cell-mediated immunity and high concentrations of
E2 augment helper T cell type 2 (Th2) responses and
humoral immunity which may be responsible for some
female as well as pregnancy-associated changes in
immune responses [126].
Another oestrogen that affects the functioning of the
immune system is oestriol (E3), which is produced dur-
ing pregnancy by the placenta. When E3 levels are high,
inflammatory responses and the symptoms of Th1-
mediated autoimmune diseases - including multiple
sclerosis - are reduced [127,128]. Whether the effects of
pregnancy on responses to 2009 H1N1 reflect the effects
of E3 on immune responses requires investigation.
Progesterone suppresses innate immune responses
[125,129]. Elevated concentrations of P4 during preg-
nancy inhibit the development of Th1 immune
responses that can lead to fetal rejection and promote
production of Th2 immune responses [130,131]. Proges-
terone also suppresses antibody production [132].
Recent data illustrate that pregnant women with severe
2009 H1N1 have lower levels of total IgG2 than healthy
pregnant women or women with only moderate H1N1
disease [133]. As IgG2 levels are enhanced in a Th1-
dependent manner, this reduction in total IgG2 may be
related to pregnancy-associated modulation of the
immune response.
Conclusions
As data from the pandemic continue to be analysed, a
number of factors should be considered by clinicians,
epidemiologists and scientists in order to better under-
stand the role of sex, gender and pregnancy on 2009
H1N1 disease.
• Age- and sex-associated differences in exposure
and severity of infection must be documented, as
many biological and behavioural differences occur
over the course of the lifespan.
• The outcome of infection is worse for females, but
the magnitude of this difference varies across coun-
tries and the differential contribution of gender and
sex in different regions of the world must be
considered.
• Excessively high innate and cell-mediated immune
responses, including the production of cytokines and
chemokines, may contribute to increased severity of
influenza in females.
• Higher antibody responses to influenza vaccines in
females may lead to an increased protection from
disease.
• Sex should be considered when effective vaccine
and antiviral dosages are determined in order to
maximize efficacy while limiting adverse side effects.
• As the outcome of influenza infection can be
worse for females, efforts should be made to increase
acceptance of vaccines in both pregnant and non-
pregnant females.
• The 2009 H1N1 infection of pregnant women
needs to be studied carefully in order to determine
the factors that are driving the increased morbidity
and mortality rates.
• Sex hormones have profound effects on the
immune responses to vaccines and infection and
should be examined in clinical samples and animal
models.
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• Animal models of infection can provide important
insights into the role of sex, pregnancy, and hor-
mones on the immune response to vaccination,
infection, and antiviral treatment.
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